Search
1135 results:
m4 Technology Transfer Summit - from idea to patient impact  
As partner of the program m4 Scouting & Incubation, a joint initiative of BioM and Munich's technology transfer organizations, Ascenion is pleased to invite you to the international "m4 Technology Transfer Summit - from idea to patient impact: Good practice in pre-seed and spin-off acceleration" to be held at Nymphenburg…  
Ascenion Information – December 2014: news, background, interviews  
Is academic technology transfer primarily concerned with money – or not? Discover what the past and current presidents of ASTP-Proton have to say on the matter in our current issue of Ascenion Information. We also report on a new therapeutic strategy for heart failure and on exciting events for technology transfer­ professionals, entrepreneurs and…  
Ascenion‘s portfolio company Clueda wins ‘Disruptive Technology Challenge’  
Clueda AG, founded in 2012, has beaten leading technology companies from Germany, Austria and Switzerland in a competition held by the international law firm Bird & Bird. They share first place with the established big data and warehouse specialist, Exasol AG. It was Clueda’s innovative approach that particularly impressed the jury. The…  
Save the date: Next BioVaria on 11 May 2015, Munich  
BioVaria brings together Europe’s top scientists and technology transfer professionals with potential licensees and investors from the international biopharmaceutical industry.In just one interactive day, it showcases around 50 licensable life-science technologies from the diagnostic, therapeutic and medical technology field originating from…  
Christmas greeting  
Dear Partners and Clients, We thank you for the enjoyable and fruitful teamwork over the past year, and wish you and your families a merry Christmas and all the best for 2015! Instead of sending Christmas cards this year, we have decided to make a donation to a public awareness campaign aimed at stopping the spread of Ebola in Liberia. There…  
Novel leukemia treatment approved by FDA  
The US Food and Drug Administration approved Amgen’s Blincyto (blinatumomab) for the treatment of patients with a certain rare form of acute lymphoblastic leukaemia (B-cell ALL). The drug is based on Amgen’s bispecific T cell engager (BiTE®) technology, designed to engage the body’s T cells, a type of immune cell, to destroy cancer cells. It…  
Christian Stein takes over presidency of ASTP-Proton  
As of mid-November 2014, Dr Christian Stein, CEO of Ascenion GmbH, is the new President of the European technology transfer association ASTP-Proton. ‘I am delighted to hand the presidency over to Christian Stein,’ says Dr Sara Matt-Leubner, CEO of transidee and previous President. ‘He is a superb Manager and an enthusiastic and passionate champion…  
ASTP-Proton supports Falling Walls Ventures  
Projects and ideas that will change our world – this is what the Falling Walls conference is all about. Each year, the meeting brings together the brightest minds in business, politics and research. Academic technology transfer has been supporting the event since 2013: both the European technology transfer association ASTP-Proton and its worldwide…  
Berlin Cures: Novel treatment targeting the cause of heart failure  
Ascenion receives equity in Charité and MDC spin-off  
BioFIT, 2-3 December 2014, Lille, France  
BioFIT is an international partnering event dedicated to technology transfer and collaborative research in the life sciences, gathering the right mix of attendees to boost licensing deals and research collaborations. The third BioFIT will build on the success of previous meetings with 800 international participants. BioFIT includes partnering,…  
Science4Life Venture Cup 2015 launched  
Entrepreneurs from all over Germany can once again submit their ideas for new companies to the the Science4Life Venture Cup 2015 – a business plan competition in the life sciences and chemistry. The ideas stage opens the 17th competition round of this start-up initiative.Practical advice, discussions with experienced coaches, professional feedback…  
EUR 5 million for amcure via Spinnovator and private investors  
amcure, a spin-off of the Karlsruhe Institute for Technology (KIT), today announces the closing of a Series A financing deal worth a total of EUR 5 million.The business objective is the development of the new cancer drug AM001, that not only stops the growth of primary tumours, but also prevents the development of metastases, and can induce the…  
‘More than Money’ – NAI publication on the value of technology transfer  
Do we need technology transfer? And if so, what for? The National Academy of Inventors (NAI) addresses these questions in a recently published article. Technology transfer is certainly not a sure route to big money – although the US professional association AUTM reported a record of USD 2.6 billion total licensing revenues for academic…  
Ascenion Information June 2014: news, background, interviews  
In our current issue, discover which spin-offs have recently been financed or acquired, how amcure is fighting metastases, who our new international partners are, and what we think about technology transfer’s ‘promise of salvation’. We have also included our ‘news in brief’ and an events calendar for you. Download „Ascenion Information June…  
7th BioVaria Attracts Leading Life-Science Innovators  
Productive knowledge transfer between industry and academia  
German Innovation Prize for Ascenion's Portfolio Company iThera Medical  
iThera Medical GmbH was announced winner of the start-up category at the German Innovation Prize award ceremony in Munich on Friday evening. iThera’s MSOT (Multispectral Optoacoustic Tomography) technology uses light to produce sound and then images: laser pulses directed onto cells or tissues generate acoustic signals that are picked up by a…  
7th BioVaria to Take Place in Munich on 6 May 2014  
Ascenion unveils first technology highlights: PET tracer for early diagnosis of Alzheimer’s disease  
BioVaria on 6 May 2014, Munich – Program Now Online  
BioVaria is Europe’s leading marketplace for life-science inventions emanating from public research institutions and universities across Europe. Take a preview : Technologies are now available at www.biovaria.org Highly innovative, commercially attractive opportunities; each one selected by BioVaria’s advisory board. Topics cover research tools,…  
Ascenion’s Portfolio Company Activaero acquired by Vectura Group  
13 March 2014, Munich -- Ascenion GmbH, the exclusive technology transfer partner of numerous life-science institutes including the Helmholtz Zentrum München, announces today that its portfolio company Activaero GmbH has been acquired by Vectura Group plc for a total consideration of €130 million. Activaero is a private German pharmaceutical…  
Welcome to the team!  
Dr Gregor Lichtfuss joined Ascenion as Project Manager at the Spinnovator at the beginning of this year. Together with his colleague Dr Katja Rosenkranz, he is looking forward to selecting projects for inclusion into the Spinnovator program and providing continuous support through the start-up founding process. This new role brings Gregor back to…  
Search results 561 until 580 of 1135